Regulatory Approval Details
NATCO Pharma Limited received tentative approval from the U.S. FDA for Olaparib tablets in 100 mg and 150 mg strengths. The approval confirms the product as bioequivalent to the reference listed drug (RLD) Lynparza® tablets manufactured by AstraZeneca Pharmaceuticals. The approval covers the indications specified in the approved labeling of the reference drug.
Manufacturing and Distribution Arrangement
NATCO will be responsible for manufacturing the Olaparib tablets. The company's partner, Alembic Pharmaceuticals Limited, will handle distribution of the product in the United States market.
Market Context and Litigation Status
The Para IV litigation concerning this product remains ongoing. According to industry sales data, Olaparib tablets had estimated sales of approximately USD 1.4 billion in the U.S. market for the 12-month period ending March 2026.
Safe Harbor Statement
The document includes a standard safe harbor statement noting that all brand names and trademarks are the property of their respective owners.
Company Background
NATCO Pharma Limited is headquartered in Hyderabad, India and develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. The company describes itself as R&D oriented and science-driven, with a focus on oncology and limited competition molecules in the US market. The company operates 9 manufacturing sites and 2 R&D facilities in India, with approvals from multiple regulatory authorities including U.S. FDA, Brazil ANVISA, Health Canada, and WHO, serving over 50 global markets.